Loading news...
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $17.5, denoting a +1.16% move from the preceding trading day.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
ADMA shares rose 13.8% over three months as demand for Asceniv surged, driving higher 2026 revenues and EBITDA targets amid margin expansion.
Adma Biologics (ADMA) concluded the recent trading session at $17.59, signifying a +1.62% move from its prior day's close.
Campbell and CO Investment Adviser LLC acquired a new stake in ADMA Biologics Inc (NASDAQ: ADMA) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 64,535 shares of the biotechnology company's stock, valued at approximately $946,000. Other hedge funds also recently modified their
ADMA Biologics was trading poorly in early 2021, near $2 per share. My thesis centered on ADMA's asset value, including plasma centers, matching its enterprise value. Strong revenue growth, insider buying, and a poison pill signaled management's confidence in profitability.
In the latest trading session, Adma Biologics (ADMA) closed at $17.7, marking a -1.28% move from the previous day.
ADMA expects 2025 revenues of approximately $510-$511 million, raising 2026 guidance on strong Asceniv demand and margin expansion.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
ADMA Biologics, Inc. (ADMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
FY 2025 Preliminary Unaudited Total Revenue of Approximately $510–511 Million Meets or Exceeds Prior Guidance Previously Provided FY 2025 Adjusted EBITDA(1) and Adjusted Net Income(2) Guidance Reiterated Year-End 2025 Cash Grew to Approximately $88 Million with an Unaudited Operating Cash Flow Estimate of ~$40 Million in 4Q 2025 2026 Expected to be ADMA's First Full Year of Yield-Enhanced Production, Supporting Anticipated Sustained Margin Expansion Strategic Plasma Network Repositioning Expected to Enhance Margins and Strengthen Long-Term Supply Visibility Positive, Statistically Significant Real-World ASCENIV™ Outcomes to be Presented at CIS in May 2026; Additional ASCENIV Data Expected Throughout 2026 Advancing SG-001 Pipeline Program with Anticipated FDA Pre-IND Submission in 2026 Ongoing Share Repurchases and Capital Structure Strengthening to Enhance Stockholder Value FY 2026 and FY 2027 Revenue Expected to be Approximately $635 Million and $775 Million, Respectively FY 2026 and FY 2027 Adjusted Net Income Expected to be Approximately $255 Million and $315 Million, Respectively FY 2026 and FY 2027 Adjusted EBITDA Expected to be Approximately $360 Million and $455 Million, Respectively ADMA Targets Greater Than $1.1 Billion in Annual Revenue in FY 2029, Representing ~20% CAGR(3) ADMA Targets Greater Than $700 Million in Adjusted EBITDA in FY 2029, Representing ~30% CAGR RAMSEY, N.J. and BOCA RATON, Fla.
In the most recent trading session, Adma Biologics (ADMA) closed at $18.34, indicating a +1.72% shift from the previous trading day.
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a podium presentation at the J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 9:45 a.m. PT.
Texas Permanent School Fund Corp trimmed its stake in ADMA Biologics Inc (NASDAQ: ADMA) by 39.3% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,932 shares of the biotechnology company's stock after selling 66,738 shares during the period. Texas Permanent
AWM Investment Company Inc. lowered its position in ADMA Biologics Inc (NASDAQ: ADMA) by 9.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,200,000 shares of the biotechnology company's stock after selling 226,431 shares during the quarter. ADMA Biologics accounts for 4.5%
Here is how Adma Biologics (ADMA) and Artivion (AORT) have performed compared to their sector so far this year.
Federated Hermes Inc. trimmed its holdings in shares of ADMA Biologics Inc (NASDAQ: ADMA) by 22.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 936,981 shares of the biotechnology company's stock after selling 267,146 shares during
Ardsley Advisory Partners LP lifted its position in ADMA Biologics Inc (NASDAQ: ADMA) by 33.3% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 400,000 shares of the biotechnology company's stock after purchasing an additional 100,000 shares during the quarter. Ardsley Advisory Partners
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.